D3 Bio has raised $108 million in a Series B financing round to support late-stage clinical development of its lead oncology candidate and advance a broader pipeline of targeted and immuno-oncology programs.
The Shanghai-based clinical-stage biotech said the round drew participation from new investors, including IDG Capital and SongQing Capital, alongside existing backers WuXi AppTec’s Corporate Venture Fund, Temasek, HSG, MPCi, and Medicxi. D3 Bio said the mix of new and returning investors reflects continued confidence in its pipeline and global development strategy.
The company plans to use the proceeds primarily to fund a global Phase III pivotal program for its lead asset, elisrasib, also known as D3S 001. D3 Bio said the pivotal trials are planned to evaluate elisrasib as both a monotherapy and in combination regimens for KRAS G12C-mutant cancers. The company expects the program to span multiple geographies, including the United States, China, and the European Union, with the goal of supporting global regulatory submissions.
Beyond the lead program, D3 Bio said the financing will also support continued development of its broader portfolio of targeted therapies and immuno-oncology candidates. The company describes its pipeline as centered on novel mechanisms and designed to pursue first-in-class or best-in-class potential, supported by proprietary clinical insight and biomarker strategies.
D3 Bio is focused on the discovery, development, and registration of new medicines in oncology and immunology, and said it retains global rights to its programs.
KEY QUOTES:
“The completion of our Series B financing demonstrates the strong confidence our investors place in our vision, scientific approach, business operations, and global development capabilities. This funding enables us to advance our lead program into late-stage clinical trials and further expand our pipeline of innovative therapies designed to benefit patients globally.”
Dr. George Chen, Founder, Chairman, And CEO, D3 Bio
“This financing demonstrates that the swift and effective pursuit of the best- or first-in-class science is meaningful to society, and validates D3 Bio’s leading innovation, scientific vision and development strategy. It also highlights the unique potential of elisrasib for individuals affected by KRAS G12C-mutant cancers.”
Dr. Antoine Yver, Member Of The Board Of Directors And Scientific Committee, D3 Bio
